Vistide Studied as Monkeypox Therapy
From Bloomberg News
Gilead Sciences Inc.’s antiviral drug Vistide is under study as a potential treatment for monkeypox, the smallpox-related virus that has struck people in Illinois, Indiana and Wisconsin, the Centers for Disease Control and Prevention said.
Vistide, sales of which were $2.6 million last year, is primarily used to treat eye infections in people with HIV.
Foster City, Calif.-based Gilead’s shares rose 91 cents, or 1.8%, to $50.58 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
